The curious thing about a biotech company is that it may know, down to a decimal point, how a therapy behaved in a trial and still be unable to explain why anybody should care. The molecule is measured. The meaning is not. Somewhere between a lab notebook and a Bloomberg terminal, scientific precision meets the blunt requirements of public language: What happened? Why now? Who benefits? And can the chief executive answer before the listener checks a phone?
KKH Advisors works in that translation layer. The New York firm advises life-sciences and digital-health companies when attention carries unusually high stakes - a launch from stealth, a financing, a clinical readout, a regulatory decision, an IPO, an acquisition or a crisis. Its tools sound ordinary: key messages, media relations, investor relations, executive counsel, training, branding and websites. The distinction is the context. In biotech, one careless adjective can imply efficacy that the data have not proved. One foggy answer can make an investor wonder whether the science is equally foggy.
The editor crosses the table
Founder and CEO Kimberly Ha did not begin as the person trying to place the story. She was the person deciding whether there was one. As Global Editor at Biopharm Insight, then part of the Financial Times Group, she learned the reporter's habit of testing a claim for gaps. At FTI Consulting, where she became a senior director, the same instinct moved into corporate positioning, transactions, crises and financial communications. KKH is the combination: newsroom skepticism applied before the interview begins.
That background explains the firm's market position. KKH is not a consumer publicity shop that happens to accept a biotech account. Its public work runs through oncology, cell and gene therapy, digital biomarkers, medtech and healthcare investing. CG Oncology listed KKH on communications around its January 2024 public offering. IN8bio names the firm on clinical and corporate announcements. Koneksa used KKH on news involving Merck and a Parkinson's digital-biomarker study. Other visible engagements reach INBRAIN Neuroelectronics, HistoSonics, Opus Genetics, Ray Therapeutics and Epicrispr Biotechnologies. The common customer is not a company of a particular size. It is a company approaching a moment when technical evidence must travel.
“We exist” is not news.Kimberly Ha, on leaving stealth
The one-shot rule
Ha's most memorable launch advice is almost comically spare. A startup should not leave stealth merely because it is tired of being quiet. It needs a hook: a discovery, a partnership, a financing, a consequential hire or meaningful validation. It also needs enough evidence to withstand the questions that attention creates. Coming out too early produces the worst kind of awareness - a promise indexed forever, before the company has a sturdy answer.
This is where KKH's work differs from the cartoon version of public relations. The product is not maximum volume. It is judgment about when volume is useful. For a pre-seed team that cannot yet explain the science or the business plan, more coverage may compound the problem. For a company with credible data but no comprehensible value proposition, disciplined translation can change who takes the meeting. Communications can clarify strong evidence; it cannot manufacture it.
One claim, five tests
How far must the science travel?
What the line items really buy
KKH's service list can be sorted into three jobs. First, decide what the company means: corporate narrative, key messages, executive positioning and the investor pitch. Second, prepare the people who must carry that meaning: chief-executive counsel, presentation coaching, media training and crisis preparation. Third, move the story through the world: reporters, investors, conferences, social channels, a brand and a website. The firm sells this as bespoke counsel and execution rather than a standardized software product; its fees are private.
The customer therefore buys senior attention and pattern recognition. A large network agency can offer more offices and a larger bench. An internal communications team can offer deeper day-to-day immersion. KKH's wager is that a specialist boutique can recognize the shape of a biotech moment faster - because it has watched other companies face the same kind of scrutiny, and because the founder knows how the newsroom will pull at a loose thread.
The Nasdaq ceremony in June 2024 supplied a tidy milestone: six years, more than 100 startups guided out of stealth, and a closing bell in Times Square. It also captured the firm's broader culture. Nasdaq credited KKH with championing underrepresented voices in life sciences and described its goal as accelerating the drug life cycle through storytelling. That is an ambitious causal chain, but not a silly one. Drugs move through institutions. Institutions move when people can evaluate an idea, trust its messenger and understand the next decision.
A press playbook anyone can steal
In a 2026 session with reporters from BioPharma Dive and Endpoints News, Ha made the firm's operating principles unusually concrete. Read the reporter's recent work. Lead with actual news. Say who is available. Give a follow-up a day. Use an embargo when the story deserves time. State what you know, and promise to return with what you do not. Establish whether a conversation is on the record, off the record or on background before the interesting sentence escapes.
Bring a real hook, supporting evidence and a clear next step. Existence alone is not a milestone.
Rehearse the hard questions about differentiation, data, risk and timing before anyone asks them live.
Know the reporter's beat and recent work. A relevant idea beats a generic list every time.
Offer context when no announcement is pending. Useful sources receive calls that cold pitchers do not.
The most revealing instruction is to think like an investor pitch. A journalist and an investor have different jobs, but both lean toward a differentiated claim, evidence that can bear weight and a reason the matter is urgent now. They also notice evasion. KKH's advice to say “I'll get back to you” is less glamorous than message discipline, but more protective of trust.
The quiet work below the headline
Much of KKH's output is visible only in reverse. Scroll to the contact block of a clinical update or financing announcement and there is the firm, responsible for what happens when a reporter replies. This is a fitting place for a company whose value is often preventative. The launch does not fizzle. The executive does not overclaim. The embargo gives a reporter enough time. The central sentence survives contact with five audiences.
There are conditions where the method has little leverage. If the data are poor, the market indifferent or the management team unprepared to answer basic questions, a cleaner narrative merely reveals the weakness faster. If a consumer campaign needs mass reach, a boutique life-sciences specialist may be the wrong machine. And if a startup wants attention before it has substance, KKH's most useful service may be recommending silence.
That restraint is the heart of the business. Biotech already contains enough uncertainty: biology, trials, regulators, capital markets and time. KKH cannot remove any of it. What it can remove is avoidable confusion. The company exists to make sure that when the science finally reaches the room, everyone is arguing about the evidence - not wondering what the speaker meant.